{
  "query": "is remdesivir an effective treatment for COVID-19",
  "keqe_expansions": [
    "Remdesivir has been a topic of significant interest and research during the COVID-19 pandemic as a potential treatment option. Several clinical trials and studies have been conducted to evaluate its effectiveness in treating the disease. While initial results from some trials have shown promising outcomes in terms of reducing hospital stay duration and improving recovery time in certain patients, there is still ongoing debate and further research needed to determine its overall efficacy.\n\nSome health authorities, such as the World Health Organization (WHO) and the National Institutes of Health (NIH), have included remdesivir in their treatment guidelines for COVID-19 patients. However, other studies have reported mixed results in terms of its benefits, with some indicating minimal or no significant impact on mortality rates.\n\nIt is important to note that the effectiveness of remdesivir may vary depending on factors such as the patient's age, the severity of their illness, and the timing of administration. As new data continues to emerge and more research is conducted, healthcare professionals and experts are constantly assessing the role of remdesivir in the treatment of COVID-19 to provide the best possible care for patients.",
    "Remdesivir has been a topic of discussion in the medical community as a potential treatment for COVID-19. Initially developed to treat Ebola, remdesivir has shown promise in laboratory studies and some clinical trials for its ability to inhibit the replication of coronaviruses. The US Food and Drug Administration (FDA) has granted emergency use authorization for remdesivir to treat COVID-19 patients in certain situations. While some studies have shown that remdesivir may help reduce recovery time in hospitalized patients with severe COVID-19, the overall evidence on its effectiveness is still evolving. Ongoing research is being conducted to further assess the safety and efficacy of remdesivir in treating COVID-19. It is essential to consult with healthcare professionals for the most up-to-date information on the use of remdesivir in the treatment of COVID-19."
  ],
  "csqe_expansions": [
    "is remdesivir an effective treatment for COVID-19 Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection. In vitro, remdesivir inhibited replication of SARS-CoV-2. Here, we investigated the efficacy of remdesivir treatment. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. A systematic benefit-risk assessment was designed and conducted to strengthen the ongoing understanding of the benefit-risk balance for remdesivir in COVID-19 treatment. The Benefit-Risk Action Team (BRAT) framework was used to assess the overall benefit-risk of the use of remdesivir as a treatment for COVID-19. We evaluated the efficacy and safety of remdesivir for the treatment of COVID-19. Systematic review in five engines, pre-print webpages and RCT registries until May 22, 2020 for randomized controlled trials (RCTs) and observational studies evaluating remdesivir on confirmed, COVID-19 adults with pneumonia and/or respiratory insufficiency. Remdesivir is a broad spectrum antiviral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19. The remdesivir, an antiviral drug, is appeared as \u2018molecule of hope\u2019 for the treatment of this disease. In this paper, we tried to describe the probable molecular mechanism of remdesivir to inhibit the RNA synthesis of SARS-CoV-2.",
    "is remdesivir an effective treatment for COVID-19 Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. We tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. A systematic benefit-risk assessment was designed and conducted to strengthen the ongoing understanding of the benefit-risk balance for remdesivir in COVID-19 treatment. The Benefit-Risk Action Team (BRAT) framework was used to assess the overall benefit-risk of the use of remdesivir as a treatment for COVID-19. We evaluated the efficacy and safety of remdesivir for the treatment of COVID-19. Systematic review in five engines, pre-print webpages and RCT registries until May 22, 2020 for randomized controlled trials (RCTs) and observational studies evaluating remdesivir on confirmed, COVID-19 adults with pneumonia and/or respiratory insufficiency."
  ],
  "top_passages": [
    "Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.\tEffective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir",
    "Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2\tEffective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir treatment",
    "Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2\tBackground Effective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. Methods To evaluate the effect of remdesivir treatment on SARS-CoV-2 disease outcome, we used the recently established rhesus macaque model of SARS-CoV-2 infection that results in transient lower respiratory tract disease. Two groups of six rhesus macaques were infected with SARS-CoV-2 and treated with intravenous remdesivir or an equal volume of vehicle solution once daily. Clinical, virological and histological parameters",
    "Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment\tBackground: There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly, given the current, ongoing pandemic. A systematic benefit-risk assessment was designed and conducted to strengthen the ongoing understanding of the benefit-risk balance for remdesivir in COVID-19 treatment by using a structured method which uses all available data. Methods: The Benefit-Risk Action Team (BRAT) framework was used to assess the overall benefit-risk of the use of remdesivir as a treatment for COVID-19 compared to standard of care, placebo or other treatments. We searched PubMed,Google Scholar and government agency",
    "Efficacy and harms of remdesivir for the treatment of COVID-19: a systematic review and meta-analysis\tBackground: We evaluated the efficacy and safety of remdesivir for the treatment of COVID-19. Methods: Systematic review in five engines, pre-print webpages and RCT registries until May 22, 2020 for randomized controlled trials (RCTs) and observational studies evaluating remdesivir on confirmed, COVID-19 adults with pneumonia and/or respiratory insufficiency. Primary outcomes were all-cause mortality, clinical improvement or recovery, need for invasive ventilation, and serious adverse events (SAE). Secondary outcomes included length of hospital stay, progression of pneumonia, and adverse events (AE). Inverse variance random effects meta",
    "Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies\tBACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19. METHODS: We systematically searched the PubMed, ClinicalTrial.Org and MedRxiv database up till May 5, 2020",
    "Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies\tBACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19. METHODS: We systematically searched the PubMed, ClinicalTrial.Org and MedRxiv database up till May 5, 2020",
    "Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment\tINTRODUCTION: There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly, given the current, ongoing pandemic. A systematic benefit-risk assessment was designed and conducted to examine the benefit-risk profile of remdesivir in COVID-19 patients compared with standard of care, placebo or other treatments. A key objective of this study was to provide a platform for a dynamic systematic benefit-risk evaluation, which starts with inevitably limited information (to meet the urgent unmet public health need worldwide), then update the benefit-risk evaluation as more data become available. METHODS: The Benefit",
    "Remdesivir in Treatment of COVID-19: A Systematic Benefit\u2013Risk Assessment\tINTRODUCTION: There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly, given the current, ongoing pandemic. A systematic benefit\u2013risk assessment was designed and conducted to examine the benefit\u2013risk profile of remdesivir in COVID-19 patients compared with standard of care, placebo or other treatments. A key objective of this study was to provide a platform for a dynamic systematic benefit\u2013risk evaluation, which starts with inevitably limited information (to meet the urgent unmet public health need worldwide), then update the benefit\u2013risk evaluation as more data become available. METHODS: The Benefit",
    "Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More\tAbstract COVID-19 is now pandemic throughout the world. Scientist, doctors are searching for effective therapy of this diseases. The remdesivir, an antiviral drug, is appeared as \u2018molecule of hope\u2019 for the treatment of this disease. USFDA approve this drug for the treatment of COVID-19. The molecular mechanism is unknown. In this paper, we tried to describe the probable molecular mechanism of remdesivir to inhibit the RNA synthesis of SARS-CoV-2. However, more detail mechanism is needed to understand mechanism of action of remdesivir."
  ],
  "combined_expansion": "is remdesivir an effective treatment for COVID-19 is remdesivir an effective treatment for COVID-19 Remdesivir has been a topic of significant interest and research during the COVID-19 pandemic as a potential treatment option. Several clinical trials and studies have been conducted to evaluate its effectiveness in treating the disease. While initial results from some trials have shown promising outcomes in terms of reducing hospital stay duration and improving recovery time in certain patients, there is still ongoing debate and further research needed to determine its overall efficacy.\n\nSome health authorities, such as the World Health Organization (WHO) and the National Institutes of Health (NIH), have included remdesivir in their treatment guidelines for COVID-19 patients. However, other studies have reported mixed results in terms of its benefits, with some indicating minimal or no significant impact on mortality rates.\n\nIt is important to note that the effectiveness of remdesivir may vary depending on factors such as the patient's age, the severity of their illness, and the timing of administration. As new data continues to emerge and more research is conducted, healthcare professionals and experts are constantly assessing the role of remdesivir in the treatment of COVID-19 to provide the best possible care for patients. Remdesivir has been a topic of discussion in the medical community as a potential treatment for COVID-19. Initially developed to treat Ebola, remdesivir has shown promise in laboratory studies and some clinical trials for its ability to inhibit the replication of coronaviruses. The US Food and Drug Administration (FDA) has granted emergency use authorization for remdesivir to treat COVID-19 patients in certain situations. While some studies have shown that remdesivir may help reduce recovery time in hospitalized patients with severe COVID-19, the overall evidence on its effectiveness is still evolving. Ongoing research is being conducted to further assess the safety and efficacy of remdesivir in treating COVID-19. It is essential to consult with healthcare professionals for the most up-to-date information on the use of remdesivir in the treatment of COVID-19. is remdesivir an effective treatment for COVID-19 Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection. In vitro, remdesivir inhibited replication of SARS-CoV-2. Here, we investigated the efficacy of remdesivir treatment. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. A systematic benefit-risk assessment was designed and conducted to strengthen the ongoing understanding of the benefit-risk balance for remdesivir in COVID-19 treatment. The Benefit-Risk Action Team (BRAT) framework was used to assess the overall benefit-risk of the use of remdesivir as a treatment for COVID-19. We evaluated the efficacy and safety of remdesivir for the treatment of COVID-19. Systematic review in five engines, pre-print webpages and RCT registries until May 22, 2020 for randomized controlled trials (RCTs) and observational studies evaluating remdesivir on confirmed, COVID-19 adults with pneumonia and/or respiratory insufficiency. Remdesivir is a broad spectrum antiviral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19. The remdesivir, an antiviral drug, is appeared as \u2018molecule of hope\u2019 for the treatment of this disease. In this paper, we tried to describe the probable molecular mechanism of remdesivir to inhibit the RNA synthesis of SARS-CoV-2. is remdesivir an effective treatment for COVID-19 Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. We tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. A systematic benefit-risk assessment was designed and conducted to strengthen the ongoing understanding of the benefit-risk balance for remdesivir in COVID-19 treatment. The Benefit-Risk Action Team (BRAT) framework was used to assess the overall benefit-risk of the use of remdesivir as a treatment for COVID-19. We evaluated the efficacy and safety of remdesivir for the treatment of COVID-19. Systematic review in five engines, pre-print webpages and RCT registries until May 22, 2020 for randomized controlled trials (RCTs) and observational studies evaluating remdesivir on confirmed, COVID-19 adults with pneumonia and/or respiratory insufficiency."
}